SCHEMBL4009789

SCHEMBL4009789

CCN1CCN(c2ncnc3ccc(-c4ccc5ncnc(Nc6ccc(N7CCOCC7)cc6)c5c4)cc23)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 7/20 0.61
HTT P42858 4/20 0.61
MAPT P10636 2/20 0.61
AHR P35869 1/20 0.61
PI4KB Q9UBF8 1/20 0.61
ALDH1A1 P00352 5/20 0.54
NPSR1 Q6W5P4 1/20 0.54
CYP3A4 P08684 7/20 0.52
CLK4 Q9HAZ1 7/20 0.52
CYP1A2 P05177 6/20 0.52
HIF1A Q16665 6/20 0.52
LMNA P02545 6/20 0.52
USP2 O75604 2/20 0.52
CYP2C19 P33261 4/20 0.51
TSHR P16473 4/20 0.51
CYP2D6 P10635 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HSD17B10 Q99714 1/20 0.49
EIF2AK2 P19525 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4007152 0.91 MAPK1 (0.72) MAPK1HTTMAPTAHRPI4KB
SCHEMBL4013714 0.90 MAPK1 (0.64) MAPK1HTTMAPTAHRPI4KB
SCHEMBL4008515 0.86 MAPT (0.80) MAPK1HTTMAPTAHRPI4KB
SCHEMBL4007596 0.86 MAPK1 (0.64) MAPK1HTTMAPTAHRPI4KB
SCHEMBL4014696 0.81 MAPT (0.63) MAPK1HTTMAPTAHRPI4KB
SCHEMBL14026142 0.81 MAPK1 (0.72) MAPK1HTTMAPTAHRPI4KB
SCHEMBL4007243 0.81 CYP1A2 (0.67) MAPK1HTTMAPTAHRPI4KB
SCHEMBL4885395 0.80 MAPK1 (0.64) MAPK1HTTMAPTAHRPI4KB
SCHEMBL4886107 0.80 MAPT (0.67) MAPK1HTTMAPTAHRPI4KB
SCHEMBL4013688 0.80 MAPK1 (0.67) MAPK1HTTMAPTAHRPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844004-B1 QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LTD (GB) 2009-06-24 EP disclosed
US-20080114008-A1 Quinazoline Derivatives as Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-05-15 US disclosed
EP-1844004-A1 QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-10-17 EP disclosed
WO-2006079833-A1 QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114008-A1 Quinazoline Derivatives as Antiviral Agents IFNAR1, C5, EIF2AK2 MAPK1 3003/4885HTT 2217/4885MAPT 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.